Please use this identifier to cite or link to this item:
http://10.1.7.192:80/jspui/handle/123456789/9787
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Abbasi, Mohammed Danish | - |
dc.date.accessioned | 2021-02-12T12:00:53Z | - |
dc.date.available | 2021-02-12T12:00:53Z | - |
dc.date.issued | 2020-04 | - |
dc.identifier.uri | http://10.1.7.192:80/jspui/handle/123456789/9787 | - |
dc.description | Guided by Dr. Mayur Patel | en_US |
dc.description.abstract | The lymphatic system is composed of lymph, lymphatic pathways such as lymphatic capillary, lymphatic vessel, lymphatic duct, etc., and certain lymphatic organs like lymph node, thymus, and spleen. The physiology of the body depends on the delivery of drugs and bioactive compounds through the lymphatic system. The lymphatic system is capable of preventing first-pass metabolism, and the lymphatic system is ideal for substances with lower bioavailability, i.e. those suffering from more hepatic metabolism. The lymph route also offers an alternative for drug delivery to treat cancer and the human immunodeficiency virus, which can pass via the lymph system. The lymphatic route plays a significant role in the movement of extracellular fluid to preserve homeostasis and in the transfer of immune cells to sites of injury. This paper offers a comprehensive analysis of the novel Nano formulations based on lipids and their lymphatic delivery. The lymphatic system's absorption and distribution of lipid-based Nano formulations depend on factors such as particle size, surface charge, molecular weight, and hydrophobicity. Nanoparticulate carriers are also addressed and their lymphatic distribution in the lymphatic systems via various routes. | en_US |
dc.publisher | Institute of Pharmacy, Nirma University, A'bad | en_US |
dc.relation.ispartofseries | PPR01031; | - |
dc.subject | PPR01031 | en_US |
dc.subject | B. Pharm Project Report | en_US |
dc.subject | Pharmaceutics | en_US |
dc.subject | lymphatic system | en_US |
dc.subject | bioavailability | en_US |
dc.subject | metabolism | en_US |
dc.subject | cancer | en_US |
dc.subject | hydrophobicity | en_US |
dc.title | Lymphatic Drug Delivery System | en_US |
dc.type | Project Report | en_US |
Appears in Collections: | B. Pharm Project Reports |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PPR01031.pdf | PPR01031 | 8.41 MB | Adobe PDF | ![]() View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.